CN107921136A - 用于治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物 - Google Patents

用于治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物 Download PDF

Info

Publication number
CN107921136A
CN107921136A CN201680040066.0A CN201680040066A CN107921136A CN 107921136 A CN107921136 A CN 107921136A CN 201680040066 A CN201680040066 A CN 201680040066A CN 107921136 A CN107921136 A CN 107921136A
Authority
CN
China
Prior art keywords
pharmaceutical composition
treatment
pharmaceutically acceptable
formula
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680040066.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·H-P·克劳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN107921136A publication Critical patent/CN107921136A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201680040066.0A 2015-07-08 2016-07-07 用于治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物 Pending CN107921136A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
CN107921136A true CN107921136A (zh) 2018-04-17

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040066.0A Pending CN107921136A (zh) 2015-07-08 2016-07-07 用于治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物

Country Status (21)

Country Link
US (3) US10413535B2 (https=)
EP (1) EP3319639B1 (https=)
JP (2) JP6752276B2 (https=)
KR (2) KR20220062688A (https=)
CN (1) CN107921136A (https=)
AU (1) AU2016290197B2 (https=)
BR (1) BR112018000112A2 (https=)
CA (1) CA2989522C (https=)
CL (1) CL2018000057A1 (https=)
ES (1) ES2835274T3 (https=)
HK (1) HK1247120A1 (https=)
IL (2) IL256770B (https=)
MA (2) MA42016A1 (https=)
MX (1) MX385229B (https=)
MY (1) MY187552A (https=)
PL (1) PL3319639T3 (https=)
RU (1) RU2018103940A (https=)
TN (1) TN2017000538A1 (https=)
UA (1) UA123728C2 (https=)
WO (1) WO2017006272A1 (https=)
ZA (1) ZA201708601B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) * 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
EP3624773A4 (en) * 2017-05-19 2021-04-07 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHOD OF USE
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
MX2022001062A (es) * 2019-07-26 2022-02-14 Allegro Pharmaceuticals Llc Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR20230110514A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 안구 장애의 치료를 위한 화합물 및 방법
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095879A1 (en) * 2000-06-16 2001-12-20 Glaxo Group Limited Novel aqueous anti-inflammatory pharmaceutical formulation
CN1330637A (zh) * 1998-12-18 2002-01-09 葛兰素集团有限公司 用于治疗炎性疾病的化合物
CN101175488A (zh) * 2005-05-17 2008-05-07 萨可德公司 治疗眼病的组合物和方法
CN101355876A (zh) * 2005-11-09 2009-01-28 康宾纳特克斯公司 治疗医学病症的方法、组合物和药剂盒
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1330637A (zh) * 1998-12-18 2002-01-09 葛兰素集团有限公司 用于治疗炎性疾病的化合物
WO2001095879A1 (en) * 2000-06-16 2001-12-20 Glaxo Group Limited Novel aqueous anti-inflammatory pharmaceutical formulation
CN101175488A (zh) * 2005-05-17 2008-05-07 萨可德公司 治疗眼病的组合物和方法
CN101355876A (zh) * 2005-11-09 2009-01-28 康宾纳特克斯公司 治疗医学病症的方法、组合物和药剂盒
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACHIM H KRAUSS等: "Effects of a novel integrin antagonist,GW559090, in an experimental dry eye model in an experimental dry eye model", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JUNE》 *
CLARA ANDONIAN: "Ocular and Systemic Pharmacokinetics of GW559090, an Alpha-4 Integrin Antagonist, in Mouse, Rabbit and Dog Following Topical Administration", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JUNE》 *

Also Published As

Publication number Publication date
UA123728C2 (uk) 2021-05-26
EP3319639B1 (en) 2020-11-18
US10413535B2 (en) 2019-09-17
RU2018103940A3 (https=) 2019-09-03
CA2989522C (en) 2022-10-18
IL256770A (en) 2018-03-29
KR20220062688A (ko) 2022-05-17
KR20180041122A (ko) 2018-04-23
ES2835274T3 (es) 2021-06-22
IL280827A (en) 2021-04-29
AU2016290197A1 (en) 2018-01-04
MX2017017163A (es) 2018-08-09
WO2017006272A1 (en) 2017-01-12
CA2989522A1 (en) 2017-01-12
US20200000786A1 (en) 2020-01-02
JP2018521126A (ja) 2018-08-02
JP2020121985A (ja) 2020-08-13
PL3319639T3 (pl) 2021-03-08
AU2016290197B2 (en) 2021-07-22
ZA201708601B (en) 2019-05-29
TN2017000538A1 (en) 2019-04-12
US20200405703A1 (en) 2020-12-31
JP6752276B2 (ja) 2020-09-09
EP3319639A1 (en) 2018-05-16
KR102440162B1 (ko) 2022-09-02
MY187552A (en) 2021-09-29
RU2018103940A (ru) 2019-08-08
MX385229B (es) 2025-03-14
BR112018000112A2 (pt) 2018-09-04
IL256770B (en) 2021-02-28
MA42016A1 (fr) 2018-03-30
US20180200240A1 (en) 2018-07-19
CL2018000057A1 (es) 2018-06-22
MA44935A1 (fr) 2019-08-30
US10751334B2 (en) 2020-08-25
HK1247120A1 (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
US10751334B2 (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
JP3345428B2 (ja) 合成甲状腺ホルマン組成物を使用した眼の処置
US20130190278A1 (en) Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
CN111032070A (zh) 用于治疗眼病的脂联素拟肽
CN1964719B (zh) 依碳酸氯替泼诺用于制备治疗干眼症的药物的用途
JP7624220B2 (ja) 自己抗体媒介性眼疾患の治療および診断
CN101005834A (zh) 干眼症治疗用滴眼液
US20170290888A1 (en) Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface
OA19750A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions.
US20170014487A1 (en) Method for treating ocular inflammation
RS64399B1 (sr) Kompozicije za lečenje oftalmoloških stanja
RU2845362C2 (ru) Лечение и диагностика опосредованных аутоантителами глазных заболеваний
HK40027227A (en) Adiponectin peptidomimetics for treating ocular disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247120

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180417

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1247120

Country of ref document: HK